is a Data Source.
The Therapeutic Structural Antibody Database (Thera-SAbDab) tracks all antibody- and nanobody-derived therapeutics recognized by the World Health Organization International Nonproprietary Names (INN) programme, recording their variable domain sequences together with format, isotype, targets, companies, approved and investigated conditions, and highest clinical trial stage. Each therapeutic is linked to its exact (100% sequence identity) and near (95-99%) structural representatives in SAbDab, and these structural mappings are refreshed alongside SAbDab's weekly updates. New therapeutics are added with each WHO INN list, and clinical status is updated from AdisInsight.
immunology, pharmacology, drug discovery, proteomics, protein structure
Warning: No license entered
Unknown
| ID | Name | URL | Category | Format | Description |
|---|---|---|---|---|---|
| therasabdab.portal | Thera-SAbDab Search Portal | search | Graphical Interface | http | Thera-SAbDab search interface for fin... |
| therasabdab.sequences-structures | Thera-SAbDab Sequences and Structures Table | TheraSAbDab_SeqStruc_OnlineDownload.csv (621.4 KB) | Product | csv | CSV table of all Thera-SAbDab therape... |
| ID | Name | URL | Category | Format | Relation | Description |
|---|---|---|---|---|---|---|
| biobtree.api | BioBTree REST API | api | Programming Interface | http | had primary source | REST API for searching identifiers an... |
Thera-SAbDab is a database of antibody and nanobody therapeutics recognized by the WHO INN programme, built by the Oxford Protein Informatics Group (OPIG) under an open-innovation agreement. It records the variable domain sequences and clinical metadata of each therapeutic and maps them to exact and near-identical structures in the Structural Antibody Database (SAbDab), which in turn draws from the Protein Data Bank.
The full therapeutic table can be downloaded as CSV or Excel from the search page. The Thera-SAbDab pages state no data license.
Created: November 12, 2026 | Last modified: November 12, 2026